Condition
Neoplasms, Gastrointestinal Tract
Total Trials
4
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
100%
4 of 4 completed with results
Key Signals
4 with results100% success
Data Visualizations
Phase Distribution
4Total
P 2 (2)
P 3 (2)
Trial Status
Completed4
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT00680901Phase 3CompletedPrimary
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
NCT00725712Phase 2CompletedPrimary
Study of GSK1363089 in Metastatic Gastric Cancer
NCT00526669Phase 2CompletedPrimary
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
NCT00486954Phase 3CompletedPrimary
Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer
Showing all 4 trials